$1.82
+0.01 (+0.55%)
Open$1.83
Previous Close$1.81
Day High$1.83
Day Low$1.82
52W High$5.68
52W Low$1.45
Volume—
Avg Volume20.9K
Market Cap19.64M
P/E Ratio—
EPS$-2.89
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,234.1% upside
Current
$1.82
$1.82
Target
$42.48
$42.48
$23.35
$42.48 avg
$52.53
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 671.1K | 1.18M | 4.21M |
| Net Income | -38,450,705 | -17,884,542 | -76,163 |
| Profit Margin | -6,407.4% | -1,605.8% | -1.8% |
| EBITDA | -37,219,618 | -17,808,595 | -73,642 |
| Free Cash Flow | — | — | -41,548 |
| Rev Growth | +131.9% | +78.7% | +17.4% |
| Debt/Equity | 250.29 | 250.29 | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |